(Reuters) - U.S. health regulators on Friday approved Japanese drugmaker Astellas Pharma Inc's drug for the treatment of two rare, often fatal invasive fungal infections that target patients with blood cancers. The Food and Drug Administration approved sale of the anti-fungal drug, Cresemba, for use against invasive aspergillosis and invasive mucormycosis. The approval had been expected after an expert advisory panel to the FDA in January voted 11-0 that Astellas had demonstrated sufficient safety and efficacy to support Cresemba for aspergillosis and 8-2 for mucormycosis.
via Health News Headlines - Yahoo News
Read More Here.. 
Lake forest health and fitness http://ift.tt/18ongQg
No comments:
Post a Comment